DOI : 10.1055/s-00000134

Diabetologie und Stoffwechsel

Issue S 01 · Volume 20 · May 2025 DOI: 10.1055/s-015-61776


Neue Dimensionen der Diabetologie – Individuell. Interdisziplinär.Innovativ.
CityCube Berlin, 28.–31.05.2025

Kongresspräsident:
Prof. Dr. med. Martin Heni
Kongresssekretärinnen:
Dr. sc. hum. Julia Hummel
Sabrina Wangler
Abstracts (HTML) Abstracts (PDF) List of Authors
P05.01
Kellerer, M; Rossing, P; Benamar, M; Cheng, AY Y; Laugesen, C; Nielsen, P H; Bajaj, H S: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Individuals with Type 2 Diabetes by Kidney Function—ONWARDS 1–5
P05.02
Kellerer, M; Riddell, M C; Heller, S R; Asong, M; Carstensen, L; Watt, S; Woo, V C: No Evidence of Increased Physical Activity–Related Hypoglycemia with Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes—ONWARDS 1–5
P05.03
Rosenstock, J; Tofé, S; Wysham, C; Thieu, V; Kiljanski, J; Lee, C; Wang, H; Patel, H; Simon, J: Near-Normoglycemia and Insulin Regression Induced by Tirzepatide in Basal Insulin–Treated Type 2 Diabetes
P05.04
Wysham, C; Rosenstock, J; Tofé, S; Thieu, V; Kiljanski, J; Lee, C; Wang, H; Patel, H; Schaum, T: Clinical Factors Associated with Insulin Regression When Adding Tirzepatide in Basal Insulin–Treated Type 2 Diabetes
P05.05
Loomba, R; Hartman, M; Lawitz, E J; Vuppalanchi, R; Boursier, J; Bugianesi, E; Yoneda, M; Behling, C; Cummings, O W; Tang, Y; Brouwers, B; Robins, D; Nikooie, A; Bunck, M C; Haupt, A; Sanyal, A J; Perakakis, N: Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial
P05.06
Überall, M; Eerdekens, M E; Engelen, S; Heine, M; Freitas, R; García Guerra, L; Quandel, T: Real-World Evidence zur Wirksamkeit wiederholter Anwendung des hochkonzentrierten (179 mg) Capsaicin-Pflasters bei schmerzhafter diabetischer peripherer Neuropathie: Steigerung der Ansprechraten und Nutzen für primäre Non-Responder
P05.07
Kersken, J: Versorgung des Diabetischen Fußsyndroms in Fußbehandlungseinrichtungen DDG in Westfalen-Lippe im 10 Jahresverlauf
P05.08
Opfermann, U; Wanner, C; Schaeffner, E; Stahl, P; Weber, C; Radowsky, F; Burckhardt, F; Scherg, F; Yaghmaei, S; Frese, T; Mader, F: InspeCKD-Studie – Die chronische Nierenkrankheit in deutschen Hausarztpraxen: Diagnosestellung hat wenig Einfluss auf die CKD-Therapie bei Patient:innen mit Typ-2 Diabetes
P05.09
Wanner, C: Long-Term Effects of Empagliflozin in CKD
P05.10
de Castro Oliveira, S; Bridi, A; Ferst, J G; Rossato, B G; Moresco, R N; Santos, G; Prado, C; Lauria, M W; da Silveira, J C; Comim, F V: Changes in plasmatic miR-126-3p, miR 217, and miR 504, reduced microparticle size, and increased total oxidative status/total antioxidant capacity in diabetes kidney disease
P05.11
Banas, M C; Kerner, R; Schultze, M; Müller, M; Birnbaum, J; Banas, B: ATLAS-CKD – Aktuelle Epidemiologie und Gesundheitskennzahlen von CKD Patient:innen in Deutschland
P05.12
Bjornstad, P; Danne, T; Tamborlane, W V; Klingensmith, G J; Schueler, E; Tartakovsky, I; Marquad, J; Zeitler, P; Willi, S M; Laffel, L M; Körner, A; Biester, T: Impact of Empagliflozin on Hyperfiltration in Youth with Type 2 Diabetes: Post Hoc Analysis of the DINAMO & DINAMO MONO Trials